促卵泡激素与绝经后女性糖尿病:系统综述与荟萃分析
该系统综述与荟萃分析检索截至2023年9月的多个数据库,纳入14项研究共7878例绝经后女性。合并分析显示,糖尿病组促卵泡激素(FSH)水平显著低于非糖尿病组(SMD -0.751,95%CI -1.129至-0.372,I²=82.46%,n=1416),高FSH与糖尿病风险降低相关(HR=0.550,95%CI 0.356-0.850,I²=0)。作者认为现有数据提示FSH水平与绝经后女性糖代谢紊乱之间存在间接关联。
要点
- 绝经后女性中,糖尿病组FSH水平显著低于非糖尿病组(SMD -0.751,95%CI -1.129至-0.372)。
- 高FSH水平与糖尿病风险降低相关(HR=0.550,95%CI 0.356-0.850)。
- FSH与空腹血糖、胰岛素及HOMA-IR均呈显著负相关。
核心结论
- 现有数据提示绝经后女性FSH水平与糖代谢紊乱之间存在间接关联,但需考虑纳入研究间的异质性及多种影响因素的复杂性,尚需进一步研究阐明潜在机制。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Scopus、Web of Sciences、Epistemonikos和Cochrane Library截至2023年9月,纳入14篇文章共7878例绝经后女性,采用纽卡斯尔-渥太华质量评估量表评估偏倚风险,大多数纳入研究为低/中度偏倚风险。
主要发现
- 糖尿病组绝经后女性FSH水平显著低于非糖尿病组(SMD -0.751,95%CI -1.129至-0.372,I²=82.46%,n=1416)。
- 糖尿病的合并效应量为0.861(95%CI 0.740-1.001,I²=80.11%)。
- 基于FSH分类水平(高 vs 低)的糖尿病合并风险估计为HR=0.550(95%CI 0.356-0.850,I²=0)。
- FSH水平与空腹血糖(r=-0.285,95%CI -0.441至-0.113,n=1229)、HOMA-IR(r=-0.241,95%CI -0.378至-0.0924,n=1229)及胰岛素(r=-0.337,95%CI -0.434至-0.232,n=959)呈显著负相关。
- 糖尿病组与非糖尿病组雌二醇水平无统计学显著差异,但促黄体生成素的SMD与FSH报告的SMD相似。
局限性
- 纳入研究间存在异质性(FSH比较I²=82.46%,糖尿病合并效应量I²=80.11%)。
- 需考虑多种影响因素的复杂性。
- 需进一步研究阐明潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The co-occurrence of hormonal changes during menopause and the risk of cardio-metabolic disorders has been well studied. OBJECTIVE: We explored the association of circulating levels of follicle-stimulating hormone (FSH) with diabetes (DM) among postmenopausal women. METHOD: In this systematic review and meta-analysis, the search was performed in PubMed, Scopus, Web of Sciences, Epistemonikos, and Cochrane Library up to September 2023. Risk of bias was assessed by Newcastle-Ottawa Quality Assessment Scale. Pooled estimates of mean differences in FSH levels were compared between postmenopausal women with and without DM. Correlations between FSH and fasting blood glucose (FBG)/insulin/homeostatic model assessment for insulin resistance (HOMA-IR) as well as pooled effect sizes with their 95% CIs for risk of DM were calculated. RESULTS: In this study, 14 articles, including 7878 postmenopausal women, met eligibility criteria. Most of the included studies had a low/moderate risk of bias. Women with DM had significantly lower FSH levels than those without DM (standardized mean difference [SMD] -0.751 [95% CI, -1.129 to -.372], I2 = 82.46%, n = 1416). The pooled effect size for diabetes was 0.861 (95% CI, 0.740-1.001; I2 = 80.11%). The pooled risk estimate for DM based on the categorical FSH levels (high vs low) was (HR = 0.550; 95% CI, 0.356-0.850, I2 = 0). The significant inverse correlation was found between FSH levels and glycemic parameters: FBG (r= -0.285 [95% CI -0.441 to -0.113]; n = 1229), HOMA-IR (r = -0.241[-0.378 to -0.0924]; n = 1229) and insulin (r = -0.337 [-0.434 to -0.232]; n = 959)]. There were no statistically significant differences between estradiol levels among diabetic and nondiabetic groups; however, the SMD for luteinizing hormone was similar to that reported for FSH. CONCLUSION: The available data indicated an indirect association between FSH levels and glucose disturbances among postmenopausal women, notwithstanding heterogeneity among included studies, and the complexity of various influential factors needs to be considered. Further efforts should be made to clarify the underlying mechanisms.
引用
- Saei Ghare Naz M, Farhadi-Azar M, Noroozzadeh M, et al. Follicle-Stimulating Hormone and Diabetes in Postmenopausal Women: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2024. PMID: 38553980. doi:10.1210/clinem/dgae198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。